Notably, pre- and post-treatment biopsies from a small cohort of patients treated with azacytidine, followed by standard chemoimmunotherapy in high-risk, newly diagnosed DLBCL, confirm SMAD1 demethylation and associated chemosensitisation [107]. The gene discussed is SMAD1; the disease is diffuse large B-cell lymphoma.